Behringwerke Aktiengesellschaft

Aventis Behring Gmbh

The General Hospital Corporation

Zlb Behring Gmbh

Sanofi-Arentideutschland Gmbh

Gerd Zettlmeissl

Ulrich Grundmann

Egon Amann

Hermann Erich Karges

Leander Lauffer

Patricia Oquendo

Achim Becker

Brian Seed

Gerhard Dickneite

Hubert Metzner

Richard Lathe

Mathias Fibi

Hans Kupper

Meng Li

Austin Smith

The invention relates to genetically engineered soluble fusion proteins composed of human proteins not belonging to the immunoglobulin family, or of parts thereof, and of various portions of the constant region of immunoglobulin molecules. The functional properties of the two fusion partners are surprisingly retained in the fusion protein.

Immunoglobulin fusion proteins, their production and use

The cDNA which codes for factor XIIIa has been isolated using a cDNA bank from human placenta and probes constructed on the basis of the amino acid sequence of factor XIIIa peptide fragments. It is possible with this cDNA not only to obtain factor XIIIa by gene manipulation in high purity but also to prepare diagnostic aids which permit the analysis of genetic factor XIIIa defects. Furthermore, it is possible on the basis of the amino acid sequence to prepare antibodies which are suitable for diagnostic aids and antibody columns.

Preparation of factor XIIIa by gene manipulation

Preparation of DNA encoding factor XIIIA

The invention provides a transgenic mouse which is heterozygous or homozygous for an at least partially defective coagulation factor XIII gene.

Transgenic coagulation factor XIII defective animal and its use for testing wound healing and bleeding

Mutants of AT III which have been advantageously modified at one or more potential glycosylation sites or at the Arg393 position are described. As a rule, combination of the mutations enhances the advantageous modifications.

Mutants of human antithrobin III and methods for their production

The invention relates to cell-free receptor binding assays which permit the binding behavior of receptor proteins in the cell membrane toward natural or artificial ligands to be investigated. This entails the particular receptor being linked to a suitable carrier molecule, preferably the heavy chain of an immunoglobulin, and being bound via the carrier, with retention of its biological property, to a suitable solid phase.

Cell-free receptor binding assays, the production and use thereof

Mutants of human antithrombin III

The invention relates to muteins of human erythropoietin (EPO) in the carboxyl terminal region which are prepared by means of recombinant DNA techniques. These mutants have advantageous properties in comparison with human wild-type EPO.

Muteins of human erythropoietin, the preparation thereof and the use

Growing community of inventors

Lahntal, Germany

Gerd Zettlmeissl